Related Experiment Video
Updated: May 10, 2026

Live/Dead Staining for Quantifying Viable but Not Culturable Cells in Manuka Honey-Treated Wound-Causing Bacteria
Published on: April 25, 2025
Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection
Anthony M Casapao1, Steven N Leonard2, Susan L Davis1,3
1Anti-Infective Research Laboratory, Pharmacy Practice Department, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Abstract:
The prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections varies in the literature, a problem complicated by the lack of routine screening procedures; however, limited data suggest that hVISA has been associated with persistent bloodstream infections (BSI) and vancomycin failure, yet these studies have been confounded by design issues. We conducted this study to compare the characteristics of patients with BSI caused by hVISA with those with vancomycin-susceptible Staphylococcus aureus (VSSA) treated with vancomycin. This retrospective, multicenter matched (1:1) cohort study compared the clinical characteristics and outcomes of hVISA and VSSA. Patients with hVISA methicillin-resistant Staphylococcus aureus (MRSA) BSI from 2004 to 2012 were matched to VSSA-MRSA BSI patients. The primary outcome was failure of vancomycin treatment, defined as a composite of persistent bacteremia (≥7 days), persistent signs and symptoms, change of MRSA antibiotic, recurrent BSI, or MRSA-related mortality. We identified 122 matched cases. The overall vancomycin failure rate was 57% (82% hVISA versus 33% VSSA; P < 0.001). The individual components of failure in hVISA versus VSSA were persistent bacteremia, 59% versus 21% (P < 0.001); change in MRSA therapy, 54% versus 25% (P = 0.001); MRSA-related mortality, 21% versus 10% (P = 0.081); and recurrence of BSI, 26% versus 2% (P < 0.001). Using logistic regression analysis and adjusting for covariates, hVISA (adjusted odds ratio [aOR], 11.1; 95% confidence interval [CI], 4.3 to 28.7) and intensive care unit (ICU) admission (aOR, 4.5; 95% CI, 1.8 to 11.6) were still independently associated with vancomycin failure. Relative to VSSA BSI, patients with hVISA were more likely to experience failure of vancomycin treatment, including persistent bacteremia and recurrence. Our results indicate that hVISA was responsible for considerable morbidity.
Insights
Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infections lead to significantly higher vancomycin treatment failure rates compared to vancomycin-susceptible Staphylococcus aureus (VSSA). This highlights hVISA as a major cause of morbidity in MRSA infections.
Area of Science:
- Infectious Diseases
- Clinical Microbiology
- Pharmacology
Background:
- Prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections is unclear due to lack of routine screening.
- Limited data suggest hVISA is associated with persistent bloodstream infections (BSI) and vancomycin treatment failure.
- Previous studies on hVISA outcomes are confounded by design limitations.
Purpose of the Study:
- To compare clinical characteristics and outcomes of patients with hVISA BSI versus vancomycin-susceptible Staphylococcus aureus (VSSA) BSI.
- To evaluate vancomycin treatment failure rates in patients with hVISA compared to VSSA.
Main Methods:
- Retrospective, multicenter, matched (1:1) cohort study.
- Compared patients with hVISA methicillin-resistant Staphylococcus aureus (MRSA) BSI (2004-2012) to VSSA-MRSA BSI patients.
- Primary outcome: vancomycin treatment failure (persistent bacteremia, persistent signs/symptoms, antibiotic change, recurrent BSI, or MRSA-related mortality).
Main Results:
- Overall vancomycin failure rate was 57% (82% in hVISA vs. 33% in VSSA; P < 0.001).
- hVISA was associated with significantly higher rates of persistent bacteremia (59% vs. 21%), change in MRSA therapy (54% vs. 25%), and recurrent BSI (26% vs. 2%).
- hVISA (aOR, 11.1) and ICU admission (aOR, 4.5) were independently associated with vancomycin failure.
Conclusions:
- Patients with hVISA BSI are significantly more likely to experience vancomycin treatment failure compared to VSSA BSI.
- hVISA infections contribute to substantial patient morbidity, including persistent bacteremia and recurrent infections.
- The findings underscore the clinical significance of hVISA and the need for improved diagnostic and treatment strategies.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Staphylococcal Skin Infections
Antimicrobial Effectiveness
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Acute Pyelonephritis II: Diagnostic Studies and Management
